Catumaxomab

Generic Name: Catumaxomab

Drug Type: Biotech

CAS Number: 509077-98-9

Unique Ingredient Identifier: M2HPV837HO

Background: Catumaxumab is a trifunctional monoclonal antibody developed for use in cancer treatment. It has affinity for T-cells, accessory immune cells, and cancer cells. Catumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites . Its market authorization was withdrawn in the EU in June 2017 at the manufacturer's request due to the company's insolvency. Catumaxumab was approved for market in Canada in May 2012 for the same condition . It is currently available under the brand name Removab.

Indication: For use in the management of malignant ascites tumours via intraperitoneal infusion where standard therapy is not available or feasible .

Associated Conditions: Ascites, Malignant

Associated Therapies: Palliative Treatment

Clinical Trials

Investigation of Safety and Tolerability of Catumaxomab in Patients With NMIBC

Phase 1

Conditions: Urinary Bladder Neoplasms

Interventions: Drug: Catumaxomab

First Posted Date: 2021-03-29

Last Posted Date: 2022-04-05

Lead Sponsor: Lindis Biotech GmbH

Target Recruit Count: 30

Registration Number: NCT04819399

Locations: 🇩🇪
Urologie Planegg, München, Germany

Catumaxomab in Patients With Non-Muscle-Invasive Bladder Cancer Who Have Failed or Are Intolerant to BCG Vaccine

Phase 1

Recruiting

Conditions: Bladder Cancer

Interventions: Drug: Catumaxomab

First Posted Date: 2021-03-16

Last Posted Date: 2023-02-13

Lead Sponsor: LintonPharm Co.,Ltd.

Target Recruit Count: 161

Registration Number: NCT04799847

Locations: 🇨🇳
Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳
The First Affiliated Hospital,Sun Yat-sen University, Guangzhou, Guangdong, China
🇨🇳
Peking University Third Hospital, Beijing, China

and more 2 locations

Comparing the Efficacy and Safety of Intra-peritoneal Infusion of Catumaxomab and Treatment of Investigator Choice in Patients With Advanced Gastric Carcinoma With Peritoneal Metastasis

Phase 3

Recruiting

Conditions: Stomach Neoplasms

Interventions: Drug: Catumaxomab
Drug: The treatment of investigator choice

First Posted Date: 2020-01-09

Last Posted Date: 2023-01-31

Lead Sponsor: LintonPharm Co.,Ltd.

Target Recruit Count: 282

Registration Number: NCT04222114

Locations: 🇨🇳
Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung, Taiwan
🇨🇳
China Medical University Hospital, Taichung, Taiwan
🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China

and more 10 locations

Feasibility and Clinical Activity of Initial Intraperitoneal Catumaxomab Followed by Chemotherapy in Patients With Recurrent Ovarian Cancer

Phase 2

Completed

Conditions: Recurrent Epithelial Ovarian Cancer

Interventions: Drug: Catumaxomab

First Posted Date: 2013-03-21

Last Posted Date: 2015-02-18

Lead Sponsor: JSehouli

Target Recruit Count: 2

Registration Number: NCT01815528

Locations: 🇩🇪
Charité Campus Virchow-Klinikum, Berlin, Germany

Treatment of Gastric Peritoneal Carcinomatosis by Association of Complete Surgical Resection of the Lesions and Intraperitoneal Immunotherapy Using Catumaxomab

Phase 2

Terminated

Conditions: Patients With Gastric Peritoneal Carcinomatosis

Interventions: Drug: Catumaxomab 140µg
Drug: Catumaxomab 100µg

First Posted Date: 2013-02-06

Last Posted Date: 2017-01-26

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 26

Registration Number: NCT01784900

Locations: 🇫🇷
Institut Gustave Roussy, Villejuif, Val de Marne, France

A Open Label, Dose Escalating Study to Evaluate the Safety and Tolerability of Ascending Intravenous (i.v.) Doses of Catumaxomab in Epithelial Cancer Patients

Phase 1

Terminated

Conditions: Epithelial Cancer Patients

Interventions: Drug: catumaxomab

First Posted Date: 2011-03-22

Last Posted Date: 2013-07-02

Lead Sponsor: Neovii Biotech

Target Recruit Count: 16

Registration Number: NCT01320020

Locations: 🇦🇹
Prof. Christian Dittrich, Wien, Austria
🇪🇸
Dr. Josep Tabernero, Barcelona, Spain
🇩🇰
Dr. Morten Soerensen, Copenhagen, Denmark

Catumaxomab as a Consolidation Therapy in Patients With Ovarian Cancer in Second or Third Clinical Disease Remission

Phase 2

Completed

Conditions: Ovarian Cancer

Interventions: Drug: Catumaxomab

First Posted Date: 2010-11-23

Last Posted Date: 2016-08-11

Lead Sponsor: Grupo Español de Investigación en Cáncer de Ovario

Target Recruit Count: 39

Registration Number: NCT01246440

Locations: 🇪🇸
Hospital Universitario 12 de Octubre, Madrid, Madrdi, Spain
🇪🇸
Hosptial Clinico Universitario de Santiago de Compostela, Santiago de Compostela, Spain
🇪🇸
Hospital Universitario Fundación Alcorcon, Alcorcon, Madrid, Spain

and more 14 locations